The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

DexCom stock was on the rise Thursday after the maker of medical technology said it had received clearance from the U.S. Food ...

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

Credit: Dexcom. The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.